The epidemiological advantage of preferential targeting of tuberculosis control at the poor.

Published Date:

04/01/2015

Source:

The International Journal of Tuberculosis and Lung Disease, Volume 19, Number 4, 1 April 2015, pp. 375-380(6)

Authors:

Andrews JR, Basu S, Dowdy DW, Murray MB

External link

Original Article

Tuberculosis (TB) remains disproportionately concentrated among the poor, yet known determinants of TB reactivation may fail to explain observed disparities in disease rates according to wealth. Reviewing data on TB disparities in India and the wealth distribution of known TB risk factors, we describe how social mixing patterns could be contributing to TB disparities. Wealth-assortative mixing, whereby individuals are more likely to be in contact with others from similar socio-economic backgrounds, amplifies smaller differences in risk of TB, resulting in large population-level disparities. As disparities and assortativeness increase, TB becomes more difficult to control, an effect that is obscured by looking at population averages of epidemiological parameters, such as case detection rates. We illustrate how TB control efforts may benefit from preferential targeting toward the poor. In India, an equivalent-scale intervention could have a substantially greater impact if targeted at those living below the poverty line than with a population-wide strategy. In addition to potential efficiencies in targeting higher-risk populations, TB control efforts would lead to a greater reduction in secondary TB cases per primary case diagnosed if they were preferentially targeted at the poor. We highlight the need to collect programmatic data on TB disparities and explicitly incorporate equity considerations into TB control plans.

Events

«

June 2017

»
S
M
T
W
T
F
S
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·

Projects

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

Statins as adjunctive host-directed therapy...

This study will investigate the role of statins in combination with the first-line regimen for TB in the mouse model. In...

Read More

Impact of diabetes on TB treatment outcomes...

This is a study to prospectively enroll and follow TB patients co-infected with diabetes and TB patients without diabetes...

Read More